Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer.
prostate cancer
prostate specific membrane antigen
radio-ligand therapy
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
30 Jun 2020
30 Jun 2020
Historique:
entrez:
8
8
2020
pubmed:
8
8
2020
medline:
8
8
2020
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA) is a cell membrane glycoprotein that is selectively expressed in prostate cells, with expression levels increasing dramatically in prostatic adenocarcinoma. PSMA-based radioligand therapy (RLT) has emerged as a viable therapeutic modality for the treatment of progressive metastatic prostate cancer. One commonly employed combination involves lutetium-177 conjugated to the ligand PSMA-617 (
Identifiants
pubmed: 32760622
doi: 10.7759/cureus.8921
pmc: PMC7392183
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e8921Informations de copyright
Copyright © 2020, Sun et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):12-19
pubmed: 29026946
J Urol. 2015 Dec;194(6):1537-47
pubmed: 26196735
Oncotarget. 2016 Mar 15;7(11):12477-88
pubmed: 26871285
J Nucl Med. 2017 Feb;58(2):312-319
pubmed: 27587707
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1663-1670
pubmed: 28624848
J Cell Biochem. 2007 Oct 15;102(3):571-9
pubmed: 17685433
J Nucl Med. 2016 Sep;57(9):1334-8
pubmed: 27056618
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454
pubmed: 28488028
World J Nucl Med. 2019 Jul-Sep;18(3):258-265
pubmed: 31516369
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):713-720
pubmed: 31781834
CA Cancer J Clin. 2008 Jul-Aug;58(4):196-213
pubmed: 18502900
Clin Nucl Med. 2020 Jan;45(1):19-31
pubmed: 31789908
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
EJNMMI Res. 2015 Dec;5(1):114
pubmed: 26099227
Pharmaceutics. 2019 Oct 29;11(11):
pubmed: 31671763
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080
pubmed: 30474706
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
J Nucl Med. 2018 Mar;59(3):459-465
pubmed: 28798031
J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):555-63
pubmed: 25620167
Clin Genitourin Cancer. 2019 Feb;17(1):15-22
pubmed: 30425003
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695-712
pubmed: 31776632
Clin Nucl Med. 2016 Jul;41(7):522-8
pubmed: 27088387